These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 24915809)

  • 1. [New challenges of personalized therapy for breast cancer to pathologists].
    Zhong X; Luo T; Zheng H; Bu H
    Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):219-21. PubMed ID: 24915809
    [No Abstract]   [Full Text] [Related]  

  • 2. Estrogen receptor in breast ductal carcinoma in situ: good cop, bad cop?
    DeCensi A; Pruneri G; Guerrieri-Gonzaga A
    J Clin Oncol; 2012 Apr; 30(12):1384-6. PubMed ID: 22393083
    [No Abstract]   [Full Text] [Related]  

  • 3. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer.
    Goldhirsch A; Glick JH; Gelber RD; Coates AS; Senn HJ
    J Clin Oncol; 2001 Sep; 19(18):3817-27. PubMed ID: 11559719
    [No Abstract]   [Full Text] [Related]  

  • 4. [Breast ductal carcinoma in situ with microinvasion: pathological review and clinical implications].
    Modesto A; Gandy C; Mery E; Filleron T; Massabeau C; Izar F; Charitansky H; Roché H; de Lafontan B
    Cancer Radiother; 2014 Mar; 18(2):107-10. PubMed ID: 24637020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developing a prognostic index for ductal carcinoma in situ of the breast. Are we there yet?
    Silverstein MJ; Craig PH; Lagios MD; Waisman JK; Lewinsky BS; Colburn WJ; Poller DN
    Cancer; 1996 Sep; 78(5):1138-40. PubMed ID: 8780555
    [No Abstract]   [Full Text] [Related]  

  • 6. TTF-1 expression in breast carcinoma-the chosen clone matters.
    Bisceglia M; Galliani C; Rosai J
    Am J Surg Pathol; 2011 Jul; 35(7):1087-8. PubMed ID: 21677546
    [No Abstract]   [Full Text] [Related]  

  • 7. Consensus conference on the classification of ductal carcinoma in situ.
    Hum Pathol; 1997 Nov; 28(11):1221-5. PubMed ID: 9385925
    [No Abstract]   [Full Text] [Related]  

  • 8. The consequence of undertreatment of patients treated with breast conserving therapy for ductal carcinoma in-situ.
    Lee DY; Lewis JL; Wexelman BA; Freedman BC; Ross RE; Tartter PI
    Am J Surg; 2013 Nov; 206(5):790-7. PubMed ID: 23866765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A confusing cancer.
    Health News; 1998 Aug; 4(10):1-2. PubMed ID: 9708039
    [No Abstract]   [Full Text] [Related]  

  • 10. Ductal carcinoma in situ of the breast: progress and controversy.
    Swallow CJ; Van Zee KJ; Sacchini V; Borgen PI
    Curr Probl Surg; 1996 Jul; 33(7):553-600. PubMed ID: 8765465
    [No Abstract]   [Full Text] [Related]  

  • 11. National treatment trends for ductal carcinoma in situ of the breast. Arch Surg 1997 Jun;132:660-665.
    Morrow M
    J Womens Health; 1998 Mar; 7(2):267-8. PubMed ID: 9555693
    [No Abstract]   [Full Text] [Related]  

  • 12. [Ductal carcinoma in situ of the breast].
    Rueda Domínguez A; Alonso Muñoz MC; Gómez Gómez A; Ojeda González B
    Med Clin (Barc); 1993 Oct; 101(14):548-56. PubMed ID: 8231402
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytologic characteristics of endocrine ductal carcinoma in situ of the breast. A case report.
    Yin H; Schinella R
    Acta Cytol; 2002; 46(5):873-6. PubMed ID: 12365222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Common questions about ductal carcinoma in situ.
    Dell DD
    Am J Nurs; 1997 May; 97(5):61-3, 65-6. PubMed ID: 9155799
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of survivin immunoexpression in the differentiation of high- and low-grade breast ductal carcinoma in situ.
    Chade MC; Piato S; Galvão MAL; Aldrighi JM; Negrini R; Mateus EF; Medeiros EM
    Einstein (Sao Paulo); 2018; 16(1):eAO4065. PubMed ID: 29694611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosing breast disease.
    Chapman B
    CAP Today; 1998 Jul; 12(7):74, 76, 80 passim. PubMed ID: 10181880
    [No Abstract]   [Full Text] [Related]  

  • 17. Is there a low-grade precursor pathway in breast cancer?
    King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
    Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No increased Ki67 expression in ductal carcinoma in situ associated with invasive breast cancer.
    Hoque A; Menter DG; Sahin AA; Sneige N; Lippman SM
    Cancer Epidemiol Biomarkers Prev; 2001 Feb; 10(2):153-4. PubMed ID: 11219775
    [No Abstract]   [Full Text] [Related]  

  • 19. Ductal carcinoma in situ of the breast--current management.
    Sharma S; Hill AD; McDermott EW; O'Higgins NJ
    Eur J Surg Oncol; 1997 Jun; 23(3):191-7. PubMed ID: 9236888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ductal carcinoma in situ of the breast.
    Silverstein MJ
    Annu Rev Med; 2000; 51():17-32. PubMed ID: 10774450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.